The FDA resolved the shortage of Eli Lilly's tirzepatide injection, a GLP-1 medication. Compounders reminded of legal restrictions on making copies of FDA-approved drugs. Hims & Hers Health expects strong demand for compounded weight loss service post-supply shortages.